Agilent Technologies Inc (A) Stake Boosted by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. raised its holdings in shares of Agilent Technologies Inc (NYSE:A) by 5.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,491 shares of the medical research company’s stock after purchasing an additional 2,600 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Agilent Technologies were worth $3,562,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. OppenheimerFunds Inc. grew its holdings in shares of Agilent Technologies by 64.0% during the second quarter. OppenheimerFunds Inc. now owns 7,636,621 shares of the medical research company’s stock valued at $472,248,000 after buying an additional 2,980,216 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Agilent Technologies by 16.9% during the third quarter. American Century Companies Inc. now owns 5,359,933 shares of the medical research company’s stock valued at $378,090,000 after buying an additional 774,771 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Agilent Technologies by 6.6% during the second quarter. Wells Fargo & Company MN now owns 2,984,214 shares of the medical research company’s stock valued at $184,544,000 after buying an additional 183,728 shares during the last quarter. Pictet Asset Management Ltd. grew its holdings in shares of Agilent Technologies by 26.9% during the third quarter. Pictet Asset Management Ltd. now owns 2,350,857 shares of the medical research company’s stock valued at $165,829,000 after buying an additional 498,430 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Agilent Technologies by 3.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 1,329,409 shares of the medical research company’s stock valued at $82,211,000 after buying an additional 49,527 shares during the last quarter.

A number of equities research analysts have recently weighed in on A shares. Goldman Sachs Group raised shares of Agilent Technologies from a “buy” rating to a “conviction-buy” rating in a report on Monday, September 17th. ValuEngine lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Morgan Stanley upped their price target on shares of Agilent Technologies from $86.00 to $89.00 and gave the company an “overweight” rating in a report on Tuesday, November 20th. Cleveland Research lowered shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a report on Monday, November 12th. Finally, Deutsche Bank upped their price target on shares of Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $78.75.

NYSE:A opened at $68.21 on Monday. Agilent Technologies Inc has a one year low of $60.42 and a one year high of $75.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.74 and a current ratio of 3.29. The firm has a market capitalization of $21.74 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 1.91 and a beta of 1.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. Agilent Technologies had a net margin of 6.43% and a return on equity of 19.84%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. Sell-side analysts anticipate that Agilent Technologies Inc will post 3.04 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 23rd. Shareholders of record on Monday, December 31st will be issued a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.96%. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Friday, December 28th. Agilent Technologies’s dividend payout ratio is presently 21.51%.

Agilent Technologies announced that its board has approved a share buyback plan on Monday, November 19th that allows the company to repurchase $1.75 billion in shares. This repurchase authorization allows the medical research company to buy up to 8.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

In other news, Director Heidi Fields sold 5,482 shares of the stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $67.73, for a total transaction of $371,295.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul N. Clark sold 2,876 shares of the stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $68.60, for a total transaction of $197,293.60. The disclosure for this sale can be found here.

TRADEMARK VIOLATION WARNING: This news story was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/26/agilent-technologies-inc-a-stake-boosted-by-meiji-yasuda-asset-management-co-ltd.html.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

See Also: How to calculate compound interest

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply